An FDA approval is one of the cleanest positive catalysts in pharma: it converts a hoped-for drug into a revenue-generating one and removes the biggest risk overhanging the stock. Approvals for combination therapies also signal the treatment's strength, o

Verdict: the approval landed, but the record says wait for confirmation

The FDA's approval of Lilly's breast cancer drug combination on September 18, 2026 removed the exact binary regulatory risk this thesis says was overhanging the stock, and the business underneath is elite — 2025 revenue of $65.2B grew 44.7% year over year, gross margin is 83.0%, and return on equity of 77.8% sits in the 91st percentile of peers, so incremental approved-product revenue flows through a highly profitable machine. The dividend story reinforces that: the payout has grown about 15.3% per year, from $3.40 per share in 2021 to $6.00 in 2025, with $6.69 paid over the trailing twelve months. But the completed backtest is the idea's own worst witness: across 60 months of daily bars it traded 377 times, won 43.2% of trades, and lost 14.6% overall with a 16.7% peak drawdown — the last twelve months still lost 1.7%. The ownership report covering the period ended June 30, 2026 (as of that report date, not current) also shows net open-market insider selling of about $2.9 million, and the latest quarter saw net margin fall 6.5 points to 30.9% and return on equity slip to 20.9%. No robust parameter setup was established — the walk-forward testing returned no recommendation — so the published configuration stands untuned. Net: wait for a daily close above both moving averages (the 20-day SMA near $1,172 and the 20-day EMA near $1,158) before entering, and size small if it does. Conviction breakdown: thesis support is decent, trade readiness is pending, risk quality is capped by the negative realized record, backtest evidence is poor, and the fundamentals trend is mixed (gross margin up, net margin down).

Trade now: LLY is one strong close away, but the evidence argues patience

LLY last closed at $1,152.93, and the strategy's long entry is **not triggered yet**. Of the three entry conditions, two are live and one is close: price above zero is met, but price above the 20-day SMA misses by about $19 (the average sits near $1,172) and price above the 20-day EMA misses by just about $5 (the average sits near $1,158). Wait means literally one daily close above both moving averages — this could trigger on the very next session, so set the alert rather than reaching for the stock today. If it triggers, the risk framework is mechanical: the hard stop sits at a 2.3% loss on the position (roughly $28 per share near current levels), the take-profit sits at a 4.7% gain (roughly $57 per share), and the first support level near $1,164 and first support at $1,163.5 frame the near-term tape. That is an effective reward:risk of about 2-to-1 per trade. Position size is capped at 25% of the book with roughly 2.3% account risk per entry via the support-based stop. The 14-day RSI at 51.2 is neutral — momentum is not stretched either way. Here is the uncomfortable part the backtest forces us to confront: this exact rule set, run completed on LLY daily bars, lost money in every window — down 14.6% over five years across 377 trades (43.2% win rate), down 9.4% over two years, and down 1.7% over the most recent twelve months, with a worst drawdown of 16.7%. A bounded walk-forward optimization was run and **no robust parameter setup was established** — fewer than two folds were profitable in every variant tested, so the published configuration stands as-is rather than a tuned version. The FDA-approval thesis (per the idea's own argument: follow-through buying over days to weeks after approval news) is plausible, but the trading rules around it have historically been a drag. If you trade the trigger, trade it small and treat the 2.3% stop as non-negotiable. Concretely: do nothing at $1,152.93. Enter only on a daily close above both the 20-day SMA and EMA, size to ~2.3% account risk, stop at −2.3%, first target at +4.7%. If price instead breaks the nearest support at $1,163.5 downward and closes below the EMA decisively, the setup goes back to sleep.

A 44.7% Growth Machine Just Got Its Regulatory Risk Removed

The idea's core claim — that an FDA approval converts hope into revenue and tends to produce follow-through buying in large pharma names…

Scores

• Conviction score breakdown: 46
• Thesis support: 65
• Trade readiness: 40
• Risk quality: 45
• Backtest evidence: 25
• Fundamentals trend: 55

Watch items

• LLY — Close vs 20-day SMA
• LLY — Close vs 20-day EMA
• LLY — RSI (14)
• LLY — Net margin (quarterly)
• LLY — Insider open-market flow
• LLY — Dividend ex-date cadence
• LLY — FDA approval announcement